Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases)

News provided by

Nov 07, 2013, 01:42 ET

DUBLIN, November 7, 2013 /PRNewswire/ --

Research and Markets
( http://www.researchandmarkets.com/research/l9klxc/autologous_stem) has announced the addition of the "Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)" report to their offering.

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This research report titled Autologous Cell Therapy (2012-2017) provides details about various ACT based treatments and their application areas. Every health regulatory body will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatments prices are not affordable, but by the intrusion of government bodies, it will definitely experience a immense market growth.

The report gives a detailed analysis about state of the art of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes latest therapy details and products which are available for licensing and approvals from various regulatory bodies. Using drivers, restraints and challenges it is forecasted for a period of five years i.e. 2012-2017. Opportunity strategy evaluation has been included which gives information for investors.

Autologous Cell Therapy technology is changing the medicinal treatments by introducing various new therapies. Its scope is vast and promising for the future despite challenges.

Key Topics Covered:

1 Introduction
2 Executive Summary
3 Autologous Cell Therapy (Act)-Technology Landscape Analysis
4 Technology Investment Potential
5 Market Landscape Analysis
6 Act - Technology Adoption Potential And Development By Geography
7 Competitive Landscape
8 Patent Analysis
9 Technology Analysis And Road Mapping
10 Analyst Insights And Recommendations
11 Company Profiles
12 Appendix
13 Glossary

Companies Mentioned

- Antria (Cro) (U.S.)
- Bioheart (U.S.)
- Brainstorm Cell Therapeutics (U.S.)
- Cytori (U.S.)
- Dendreon Corporation (U.S.)
- Fibrocell (U.S.)
- Genesis Biopharma (U.S.)
- Georgia Health Sciences University (U.S.)
- Neostem (U.S.)
- Opexa Therapeutics (U.S.)
- Orgenesis (U.S.)
- Regenexx (U.S.)
- Regeneus (Australia)
- Tengion (U.S.)
- Tigenix (Belgium)
- Virxsys (U.S.)